Drugmaker Eli Lilly is hoping tirzepatide, sold as Mounjaro and Zepbound for diabetes and weight loss, will become the first drug approved to treat sleep apnea, which it says affects some 80 million Americans, many of whom go undiagnosed and untreated.
